Clinical Pharmacology and Drug Toxicity Practice Questions

Q: Which of the following is teratogenic?

Vitamin A. ***Vitamin A*** - High doses of **preformed vitamin A (retinoids)**, both natural and synthetic, can be teratogenic, leading to birth defects. - Excessive vitamin A intake during pregnancy is associated with abnormalities affecting the **craniofacial, central nervous, and cardiovascular systems**. *Folate* - Folate is an **essential nutrient for fetal development** and is crucial for preventing neural tube defects. - It is **not teratogenic**; in fact, supplementation is routinely recommended to pregnant women. *Cyanocobalamin* - **Cyanocobalamin (Vitamin B12)** is not considered teratogenic and plays a vital role in fetal growth and neurological development. - Deficiencies, rather than excesses, are a concern during pregnancy, potentially leading to developmental issues. *Vitamin C* - **Vitamin C** is an antioxidant and is not known to be teratogenic; it is an important nutrient during pregnancy. - While extremely high doses could theoretically have mild side effects, it does not cause birth defects and is generally considered safe.

Q: After how many weeks of metoclopramide use does the risk of developing tardive dyskinesia significantly increase?

12. ***12 weeks***- The FDA issued a **BLACK BOX WARNING** limiting metoclopramide use to **≤12 weeks** due to significantly increased risk of **tardive dyskinesia** beyond this threshold- This is the critical duration where re-evaluation of therapy necessity is mandated to minimize irreversible neurological complications- **Clinical guideline**: Maximum duration of 12 weeks for most indications*8 weeks*- While adverse effects can occur with any duration of use, the **significant risk threshold** for tardive dyskinesia is at 12 weeks, not 8- This duration is still within the safer treatment window*16 weeks*- This exceeds the **FDA-recommended maximum duration**- By 16 weeks, the risk is already substantially elevated, making this well beyond the threshold where risk "significantly increases"*20 weeks*- This represents prolonged exposure far exceeding safety guidelines- The significant risk increase occurs much earlier (at 12 weeks), making this an extended period of inappropriate use

Q: Why is clopidogrel preferred over ticlopidine?

Lower incidence of neutropenia and thrombocytopenia. **Lower incidence of neutropenia and thrombocytopenia** - **Clopidogrel** has a significantly **lower risk** of causing severe hematologic side effects like **neutropenia** and **thrombocytopenia** compared to ticlopidine. - This improved safety profile makes clopidogrel the **preferred antiplatelet agent** in clinical practice due to reduced monitoring requirements and increased patient safety. *Lower incidence of dyslipidemia* - Neither clopidogrel nor ticlopidine are primarily associated with a significant incidence of **dyslipidemia** as a direct side effect. - **Dyslipidemia** is more commonly managed through lifestyle changes and lipid-lowering medications like statins. *Lower incidence of hyperglycemia* - Both clopidogrel and ticlopidine are not known to directly cause or exacerbate **hyperglycemia**. - **Hyperglycemia** is typically associated with diabetes mellitus or certain medications like corticosteroids. *Lower incidence of postural hypotension* - **Postural hypotension** is not a common or significant side effect associated with either clopidogrel or ticlopidine. - **Postural hypotension** is more frequently linked to medications affecting the autonomic nervous system or volume status.

Q: Which drug is given in the pain due to diabetic neuropathy?

Gabapentin. ***Gabapentin*** - **Gabapentin** is a first-line agent often prescribed for neuropathic pain, including that caused by **diabetic neuropathy**. - It works by modulating voltage-gated **calcium channels**, reducing neurotransmitter release in the pain pathways. *Lamotrigine* - While an antiepileptic drug, **lamotrigine** is primarily used for **epilepsy** and **bipolar disorder**. - It is not a first-line treatment for **diabetic neuropathic pain**. *Na valproate* - **Sodium valproate** is an anticonvulsant and mood stabilizer, mainly used for epilepsy, **bipolar disorder**, and **migraine prophylaxis**. - It is not typically recommended for the management of **diabetic neuropathic pain**. *Morphine* - **Morphine** is a strong opioid analgesic used for severe acute or chronic pain. - While it can alleviate pain, it is generally considered a **second-line or third-line agent** for **neuropathic pain** due to risks of dependence and side effects.

Q: Which of the following is not a commonly reported adverse effect of imatinib?

Hepatotoxicity. ***Hepatotoxicity*** - **Hepatotoxicity IS a commonly reported adverse effect** of imatinib, occurring in approximately **10-15% of patients** with elevated liver enzymes. - However, compared to the **extremely high frequency** of fluid retention manifestations (occurring in 50-70% of patients), hepatotoxicity is **relatively less characteristic** of imatinib's adverse effect profile. - **Regular liver function monitoring** is required during imatinib therapy, and the FDA labeling includes hepatotoxicity warnings. - Among the listed options, this represents the **least predictable** adverse effect compared to the nearly universal fluid retention issues. *Periorbital edema* - **Fluid retention** with **periorbital edema** is the **most characteristic and common** adverse effect of imatinib, occurring in **60-70% of patients**. - This is due to imatinib's effect on **PDGF and c-KIT receptors** affecting vascular permeability and interstitial fluid regulation. - Often one of the first adverse effects patients notice. *Myalgia* - **Muscle aches and cramps** occur in **40-50% of patients** taking imatinib. - Often managed with **magnesium supplementation**, hydration, and dose adjustment. - Represents a very commonly reported musculoskeletal adverse effect. *Pleural effusion* - Part of the **fluid retention spectrum** associated with imatinib therapy. - Occurs in **5-10% of patients**, particularly with higher doses or in elderly patients. - May require dose reduction, diuretics, or temporary drug discontinuation in severe cases.

Q: Which of the following is an adverse effect of methysergide?

Endocardial fibrosis. ***Endocardial fibrosis*** - Methysergide is known to cause **retroperitoneal, pleuropulmonary, and endocardial fibrosis** due to its serotonergic action. - This adverse effect can lead to **restrictive cardiomyopathy** and valvular heart disease if treatment is prolonged. *Metabolic syndrome* - Metabolic syndrome is characterized by a cluster of conditions such as **increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels**. - It is often associated with antipsychotics and other medications, but not a primary adverse effect of methysergide. *Peyronie's syndrome* - **Peyronie's disease** involves the development of **fibrous scar tissue** inside the penis, causing curved, painful erections. - While it involves fibrosis, it is not a recognized adverse effect of methysergide. *Dry mouth* - Dry mouth, or **xerostomia**, is a common side effect of many medications, particularly those with anticholinergic properties. - While some medications can cause dry mouth, it is not a characteristic or significant adverse effect associated with methysergide, which is known for its fibrotic complications.

Q: Which of the following causes retinal pigmentation?

Chloroquine. ***Chloroquine*** - Chloroquine can cause **retinal toxicity**, leading to **pigmentary changes** and potentially irreversible vision loss, particularly with prolonged use or high doses. - The characteristic finding is often described as **"bull's eye maculopathy,"** a central area of depigmentation surrounded by a ring of hyperpigmentation in the macula. *Quinine* - Quinine is known for causing **cinchonism**, which includes symptoms like **tinnitus**, headache, and blurred vision, but not typically retinal pigmentation. - While it can cause **visual disturbances**, these are usually related to **optic nerve toxicity** or vascular changes, not direct pigmentary retinopathy. *Mefloquine* - Mefloquine is associated with **neuropsychiatric side effects**, such as vivid dreams, anxiety, depression, and hallucinations, but not retinal pigmentation. - Its adverse ocular effects are less common than with chloroquine and do not typically involve permanent pigmentary changes to the retina. *Atovaquone* - Atovaquone is generally well-tolerated with common side effects including gastrointestinal upset, headache, and rash. - It is **not known to cause retinal pigmentation** or significant ocular toxicity.

Q: Which T cell surface molecule's co-stimulatory function is blocked by Abatacept?

CD28. ***CD28*** - **Abatacept** is a fusion protein that binds to **CD80** and **CD86** on antigen-presenting cells (APCs). - This binding prevents the interaction of **CD80/CD86** with **CD28** on T cells, thereby blocking the critical co-stimulatory signal required for full T-cell activation [1]. *CD11* - **CD11** is part of the **integrin** family (e.g., CD11b/CD18, known as Mac-1 or CR3) and is involved in cell adhesion and migration, primarily on myeloid cells. - It does not directly participate in the **T-cell co-stimulation pathway** targeted by abatacept. *CD20* - **CD20** is a B-cell specific surface molecule that is the target of **rituximab**, a monoclonal antibody used in various lymphomas and autoimmune diseases. - It is not expressed on T cells and therefore not involved in **T-cell co-stimulation** blocked by abatacept. *CD22* - **CD22** is a **B-cell co-receptor** molecule involved in B-cell activation and signaling, acting as a negative regulator. - It does not play a direct role in the **co-stimulatory signals** between APCs and T cells that are modulated by abatacept.

Q: Nux vomica seeds contain 2 alkaloids, strychnine and which other alkaloid?

Brucine. ***Brucine*** - **Nux vomica seeds** (Strychnos nux-vomica) are known to contain two primary alkaloids: **strychnine** and **brucine**. - **Brucine** is structurally similar to strychnine but is generally less toxic and contributes to the bitter taste of the seeds. *Hyoscine* - **Hyoscine** (scopolamine) is an alkaloid found in plants like **deadly nightshade** (Atropa belladonna) and **Datura**. - It is known for its **anticholinergic** properties and is not a primary alkaloid of Nux vomica. *Hyoscyamine* - **Hyoscyamine** is another **tropane alkaloid** found in plants such as **henbane** (Hyoscyamus niger) and **deadly nightshade**. - It also exhibits **anticholinergic** effects and is not associated with Nux vomica seeds. *Atropine* - **Atropine** is a well-known **tropane alkaloid** found in plants of the **Solanaceae family**, like **Atropa belladonna**. - It is used as a potent **anticholinergic** agent and is not a constituent of Nux vomica.

Q: What is the approximate incidence of hepatotoxicity in patients receiving HAART?

10%. ***10%*** - The incidence of **hepatotoxicity** among patients on **HAART** (Highly Active Antiretroviral Therapy) is estimated to be around 10%. - This adverse effect can range from mild, asymptomatic enzyme elevations to **severe liver injury**. *20%* - While hepatotoxicity is a known complication of HAART, an incidence of 20% is generally considered higher than the average reported rates in most studies. - Higher rates might be encountered in specific high-risk populations, such as those with pre-existing liver disease or co-infection with viral hepatitis, but not as a general approximation. *30%* - An incidence of 30% for HAART-induced hepatotoxicity is significantly higher than typically observed and would suggest a higher level of risk than is generally presented in clinical literature. - Such high rates are usually associated with specific, older regimens or very vulnerable patient groups. *40%* - An incidence of 40% is exceptionally high for HAART-induced hepatotoxicity and would indicate a severe and frequent adverse reaction, which is not characteristic of modern HAART regimens. - This figure is not representative of the general incidence in patients receiving contemporary antiretroviral therapy.

Question 1

Which of the following is teratogenic?

Accepted Answer

Vitamin A

Answer

Folate

Answer

Cyanocobalamin

Answer

Vitamin C

Question 2

After how many weeks of metoclopramide use does the risk of developing tardive dyskinesia significantly increase?

Accepted Answer

12

Answer

8

Answer

16

Answer

20

Question 3

Why is clopidogrel preferred over ticlopidine?

Accepted Answer

Lower incidence of neutropenia and thrombocytopenia

Answer

Lower incidence of dyslipidemia

Answer

Lower incidence of hyperglycemia

Answer

Lower incidence of postural hypotension

Question 4

Which drug is given in the pain due to diabetic neuropathy?

Accepted Answer

Gabapentin

Answer

Lamotrigine

Answer

Na valproate

Answer

Morphine

Question 5

Which of the following is not a commonly reported adverse effect of imatinib?

Accepted Answer

Hepatotoxicity

Answer

Myalgia

Answer

Periorbital edema

Answer

Pleural effusion

Question 6

Which of the following is an adverse effect of methysergide?

Accepted Answer

Endocardial fibrosis

Answer

Metabolic syndrome

Answer

Peyronie's syndrome

Answer

Dry mouth

Question 7

Which of the following causes retinal pigmentation?

Accepted Answer

Chloroquine

Answer

Quinine

Answer

Mefloquine

Answer

Atovaquone

Question 8

Which T cell surface molecule's co-stimulatory function is blocked by Abatacept?

Accepted Answer

CD28

Answer

CD11

Answer

CD20

Answer

CD22

Question 9

Nux vomica seeds contain 2 alkaloids, strychnine and which other alkaloid?

Accepted Answer

Brucine

Answer

Hyoscine

Answer

Hyoscyamine

Answer

Atropine

Question 10

What is the approximate incidence of hepatotoxicity in patients receiving HAART?

Accepted Answer

10%

Answer

20%

Answer

30%

Answer

40%

Clinical Pharmacology and Drug Toxicity — MCQs

Clinical Pharmacology and Drug Toxicity — MCQs

On this page

Practice by Chapter

Want unlimited practice?